Mission
BIOPHYTIS is a biotechnology company created in 2006, specialising in diseases associated with aging, particularly those affecting muscular and visual functions.
Aging science
By understanding the relationship between natural active substances and degeneration processes BIOPHYTIS is able to identify families of substances capable of acting directly on the mechanism of the disease.
Pipeline
BIOPHYTIS has a portfolio of first-in-class drug candidates, at various stages of development, for treating certain indications of sarcopenia and AMD, for which there is currently no treatment.
News
08 December 2017

Biophytis Presents 4 Posters on Sarconeos at 10th International Conference on Cachexia, Sarcopenia, and Wasting Disorders (SCWD). Read the Press Release

04 December 2017

Biophytis has FAMHP Approval to conduct SARA-INT phase 2b Interventional Study of Sarconeos in Sarcopenia in Belgium. Read the Press Release